Xinlietai: The clinical trial application for the drug SAL0140 has been accepted.

Xintai announced that the company's independently developed innovative small molecule drug SAL0140 tablets have received acceptance for clinical trial application for new indications from the National Medical Products Administration. SAL0140 is the company's in-house developed aldosterone synthase inhibitor with independent intellectual property rights, intended for indications including uncontrolled hypertension, chronic kidney disease, and primary aldosteronism. Currently, SAL0140 is about to start Phase II clinical trials. If successful in research and market approval, it will provide new medication options for patients and enrich the company's innovative product pipeline in the field of chronic diseases. However, drug development has a long cycle and high risks, so it will not have a tangible impact on the company's performance in the short term.